オナルツズマブ(遺伝子組換え) 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 抗MET抗体
説明
Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor.
臨床応用
Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) .
オナルツズマブ(遺伝子組換え) 上流と下流の製品情報
原材料
準備製品